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A b s t r a c t
Aim: The AIRWAYS-2 cluster randomised controlled trial compared the i-gel supraglottic airway device
(SGA) with tracheal intubation (TI) as the first advanced airway management (AAM) strategy used by
Emergency Medical Service clinicians (paramedics) treating adult patients with non-traumatic out-of-
hospital cardiac arrest (OHCA). It showed no difference between the two groups in the primary outcome
of modified Rankin Scale (mRS) score at 30 days/hospital discharge. This paper reports outcomes to 6
months.
Methods: Paramedics from four ambulance services in England were randomised 1:1 to use an i-gel SGA
(759 paramedics) or TI (764 paramedics) as their initial approach to AAM. Adults who had a non-traumatic
OHCA and were attended by a participating paramedic were enrolled automatically under a waiver of
* Corresponding author at: Faculty of Health and Life Sciences, University of the West of England, Glenside Campus, Bristol BS16 1DD, UK.
E-mail address: Jonathan.Benger@uwe.ac.uk (J.R. Benger).
https://doi.org/10.1016/j.resuscitation.2020.09.026
0300-9572/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
R E S U S C I T A T I O N 1 5 7 ( 2 0 2 0 ) 7 4 8 2
Available online at www.sciencedirect.com
Resuscitation
jou r n al ho m epag e: ww w.els evier .c o m/lo c ate / res u sc i ta t ion
consent. Survivors were invited to complete questionnaires at three and six months after OHCA.
Outcomes were analysed using regression methods.
Results: 767/9296 (8.3%) enrolled patients survived to 30 days/hospital discharge and 317/767
survivors (41.3%) consented and were followed-up to six months. No significant differences were found
between the two treatment groups in the primary outcome measure (mRS score: 3 months: odds ratio
(OR) for good recovery (i-gel/TI, OR) 0.89, 95% CI 0.691.14; 6 months OR 0.91, 95% CI 0.711.16).
EQ-5D-5L scores were also similar between groups and sensitivity analyses did not alter the findings.
Conclusion: There were no statistically significant differences between the TI and i-gel groups at three
and six months. We therefore conclude that the initially reported finding of no significant difference
between groups at 30 days/hospital discharge was sustained when the period of follow-up was
extended to six months.
Keywords: Heart arrest, Airway management, Tracheal intubation, Laryngeal mask, Survival rate, Health-related quality of life
Introduction
Survival rates following out-of-hospital cardiac arrest (OHCA) remain
disappointingly low. Of the nearly 30,000 people who receive
resuscitation for OHCA in England annually, only 25% achieve a
return of spontaneous circulation (ROSC), and 8% are discharged
from hospital alive.1
The earlier an intervention is provided in OHCA the greater its
potential to increase survival.2 If basic life support and initial
defibrillation of a shockable rhythm does not result in ROSC, the
attention of emergency medical services (EMS) clinicians (para-
medics) turns to airway management and drug delivery.3
However, optimal airway management during OHCA has been
an enduring area of uncertainty, with very little high-quality
research on which to base treatment recommendations.4 Options
range from basic airway intervention to advanced procedures such
as the insertion of a supraglottic airway (SGA) or tracheal
intubation (TI), which is considered the “gold standard” of
advanced airway management.5
Large observational studies have shown an association between
survival following OHCA and the use of basic airway management
techniques, when compared with either SGA or TI.6 However these
studies are prone to residual confounding and resuscitation time
bias.7,8 As a result, methodologies to complete high-quality random-
ised controlled trials (RCTs) of alternative advanced airway
management (AAM) strategies in the early stages of cardiac arrest
have been developed.9
During 2018, two RCTs of AAM during OHCA were published.
Both compared an SGA with TI as the initial AAM strategy adopted
by paramedics treating non-traumatic OHCA in adults. The
Pragmatic Airway Resuscitation Trial (PART) compared the
laryngeal tube SGA with TI in 3004 patients and found a statistically
significant benefit in survival to 72 h and hospital discharge, and a
favourable neurological status at hospital discharge, for those
patients randomised to the laryngeal tube.10 At the same time, we
published the AIRWAYS-2 trial which showed no difference in good
functional outcome (modified Rankin Scale (mRS) score of 03) at
hospital discharge or 30 days between 9296 patients randomised to
either the i-gel SGA or TI.11
Whilst early outcomes are valuable measures in studies involving
OHCA patients, there is an increasing recognition of the importance of
longer-term outcomes and functional recovery following OHCA,
including quality of life in survivors.12 The aim of this paper was
therefore to compare the secondary outcomes of mRS score and
EuroQol-5D (EQ-5D) at three and six months after OHCA between
groups of patients in the AIRWAYS-2 trial managed by paramedics
randomised to use either the i-gel or TI as their initial AAM strategy
when treating adult patients following OHCA.
Methods
The AIRWAYS-2 trial methodology has been reported previously.11,13
In summary, we completed a cluster RCT of paramedics from four
large EMS provider organisations (ambulance services) in England
covering approximately 21 million people. 1523 paramedics volun-
teered to participate and were randomised 1:1 to use an i-gel SGA
(759 paramedics) or TI (764 paramedics) as their initial AAM strategy
when attending adult patients with non-traumatic OHCA.
Randomisation and case ascertainment
Individual patient randomisation was considered impractical due to
the risk that research procedures would delay life-saving treatment.
We therefore chose to designate paramedics as the unit of random-
isation, thereby creating a relatively large number of clusters
containing a relatively small number of patients on average. This
had the benefit of minimising the intra-cluster correlation and more
closely approximating individual patient randomisation than would be
the case if larger clusters were used. It was not possible to blind
paramedics to the treatment allocation. Therefore, it was necessary to
enrol all eligible patients into the trial to avoid the risk of selection bias,
(e.g. to avoid paramedics selectively enrolling patients on the basis of
their predicted outcome).14 This complete case ascertainment was
achieved by supplementing routine case reporting by participating
paramedics with daily review of all cardiac arrests occurring in the four
participating EMS provider organisations (ambulance services) and
cross-referencing with routinely collected audit data that are submitted
to a national OHCA registry.1
Patient enrolment
Automatic patient enrolment proceeded under a waiver of consent
provided by the Confidentiality Advisory Group (CAG: reference 14/
CAG/1030). Ethics review and approval was provided by South
Central - Oxford C Research Ethics Committee (REC: reference 14/
SC/1219). This included a process of written informed consent for
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participating paramedics and for surviving patients (or a personal
consultee for surviving patients without mental capacity). The main
disadvantage of automatic enrolment was that many enrolled patients
did not receive any AAM. There was also an increased risk that eligible
patients might not be recognised as such by the participating
paramedic, leading to protocol deviations. Paramedics were given the
clinical freedom to deviate from the trial protocol if they felt that a
particular approach to airway management was in the patient's best
interests.
Patient inclusion criteria
Patient inclusion criteria were: known or believed to be 18 years of age
or older; non-traumatic OHCA; attended by a paramedic participating
in the trial who was either the first or second paramedic to arrive at the
patient's side; resuscitation commenced or continued by paramedics
or EMS personnel. Patient exclusion criteria were: detained in the
Prison Service; previously recruited to the trial (determined retro-
spectively); resuscitation deemed inappropriate (using guidelines
based on those of the Joint Royal Colleges Ambulance Liaison
Committee)15; advanced airway already in place (inserted by another
paramedic, doctor or nurse) when a paramedic participating in the trial
arrived at the patient's side; known to be already enrolled in another
pre-hospital RCT; patient mouth opening <2 cm.
Intervention
The intervention was the insertion of a second generation SGA (i-gel:
Intersurgical, Wokingham, UK), which is the SGA most commonly
used by paramedics in England.16 This was compared with TI using
direct laryngoscopy and an intubating bougie. A standard approach to
airway management in the trial, from basic to advanced techniques,
was agreed by participating ambulance services. This included the
use of bag-mask ventilation and simple airway adjuncts before AAM.
In all other respects care proceeded as usual, with resuscitation
following standard international guidelines.17
Follow-up procedures
All enrolled patients who survived to hospital discharge were followed-
up by a member of the local research team who consulted with the
clinical staff caring for the patient to determine the optimal time to
approach the patient and/or their family to seek consent. Consent was
sought from the patient or from a personal consultee if the patient was
judged to lack capacity. Each patient or consultee was able to choose
either active follow-up (collection of routinely available data combined
with telephone and/or postal contact at 30 days/hospital discharge,
and three and six months after cardiac arrest), passive follow-up
(collection of routinely available data only, with no further patient
contact) or no further data collection. In cases where a consultee
opinion was obtained, and active follow-up chosen, the patient's
capacity was re-assessed at the three- and six-month follow-up. If an
initially incapacitated patient regained capacity, consent to continue
their involvement in the trial was sought from the patient. The mortality
status of patients who consented to follow-up was ascertained from
national record systems. The mortality status of all other survivors was
obtained from Hospital Episode Statistics data provided by NHS
Digital (under HRA CAG approval) where linkage was possible.
Outcomes
For patients who provided active consent, the mRS score was
measured at three and six months after the index OHCA. The mRS
score, which incorporates both functional outcome and survival, is
widely used in OHCA research and comprises a seven-point scale (0
6) with lower scores representing better recovery.18 Patients who die
are given a score of six. The mRS scores were dichotomised into good
recovery (score 03) and poor recovery (score 46). The EuroQol
(EQ-5D-5L) is a validated measure of health-related quality of life and
has been used widely in OHCA survivors.19 The EQ-5D-5L descriptive
system comprises 5 domains: mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression. The EQ-5D-5L visual analogue
scale (VAS) records a person's self-rated health with a range of 0
100. The EQ-5D-5L descriptive system and VAS were measured at
30 days/hospital discharge (whichever comes first), three and six
months after the index OHCA for patients who consented to active
follow-up and had survived to these timepoints. The EQ-5D-5L index
scores (index) were calculated from the descriptive system responses
by mapping onto the EQ5D-3L value set.20 Patients who had died
were given a value of 0 for both the index and VAS scores.
Statistical analysis
The primary analysis included participants with outcome data
(complete-case analysis). The effect of missing data was examined
with two sensitivity analyses. The first (‘worst-case’ scenario)
assigned the worst possible score to known survivors with missing
data, whilst patients for whom the survival status was unknown were
assumed to have died. The second sensitivity analysis (‘imputed case’
scenario), used multiple imputation (60 imputations). Imputations was
performed using the ICE command in Stata v15.1 (StataCorp) and
estimates were combined using Rubin's rules. The imputation model
included the following variables: age, sex, length of intensive care unit
(ICU) stay, treatment group, ambulance provider organisation,
paramedic experience, distance from base ambulance station, and
index, VAS and mRS scores at 30 days/hospital discharge, three
months and six months timepoints (see supplement for further
details).
Logistic regression was used to analyse the dichotomised mRS
scores with paramedic fitted as a random effect. A two-part binomial-
beta model was used to analyse the EQ-5D-5L index and VAS scores.
The scores of survivors were transformed for the purposes of
modelling using the following transformation:
y 0 ¼ y  a
b  a
yn ¼ y
0ðN  1Þ þ 1=2½ 
N
where y is the outcome (index or VAS score), b is the highest possible
score (index: 1, VAS: 100), a is the smallest possible score (index:
0.59, VAS: 0), N is the total number of survivors with data and yn
is the transformed score. This transformation ensured that the
transformed scores were between 0 and 1 (excluding 0 and 1) which is
required for beta regression.21 The two-part binomial-beta model
produces two treatment estimates.22 The first (binomial part) is the
odds ratio for survival (‘alive vs dead’) with an estimate greater than 1
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favouring i-gel over TI. The second estimate (beta part) relates to the
quality of life of survivors (‘given patient survived’). Again, an estimate
greater than 1 indicates a better quality of life in the i-gel group over the
TI group.
All models were fitted to each timepoint separately as convergence
issues prevented the fitting of longitudinal models. To allow for
clustering of paramedics in the two-part binomial-beta models,
confidence intervals were estimated using clustered bootstrapping
(see supplement for further details). The clustered bootstrap and two-
part binomial-beta model was performed in SAS v9.4. All other
analyses were performed in Stata v15.1 (StataCorp).
Results
In total, 9296 patients were enrolled in the AIRWAYS-2 trial (4410 TI,
4886 i-gel). 767/9296 (8.3%) of patients survived to 30 days/hospital
discharge and 402/767 (52.5%) consented to active follow-up. Of the
402 patients who consented to active follow-up, 388 (96.5%) were
known to have survived to six months post-OHCA, 13 had died and the
survival status at six months was unknown for 1 patient. All 402
patients who consented to active follow-up completed questionnaires
at 30 days/hospital discharge. Completion rates at three months and
six months were 300/396 (153/194 TI, 147/202 i-gel), and 317/388
(159/190 TI, 158/198 i-gel) respectively (Fig. 1).
In the period between 30 days/hospital discharge and six months
post-OHCA, the proportion of patients with a mRS score of 0 (no
symptoms) increased whilst the proportion of patients with a mRS
score of 5 (severe disability requiring constant nursing care)
decreased (Table 1, Supplement Fig. 1). All patients with a score
of 5 at six months also had a score of 5 at 30 days/hospital discharge
(Supplement Fig. 2). Most patients with a mRS score of 0 at three and
six months had improved since 30 days/hospital discharge (Supple-
ment Figs. 2 and 3). Of patients who had a mRS score of 0 at six
months, the majority also had a score of 0 at three months
(Supplement Fig. 3). Of the 66 patients with a mRS score of 5 at
30 days/hospital discharge, 12/66 (18.2%) died before 3 months, 11/
66 (16.7%) improved and 5/66 (7.6%) stayed the same; data were
missing for the remaining 38 (57.6%) (Supplement Fig. 4).
In the period between 30 days/hospital discharge and six months
post-OHCA, the proportion of patients with a mRS score of 0 (no
symptoms) increased whilst the proportion of patients with a mRS
score of 5 (severe disability requiring constant nursing care)
decreased (Table 1, Supplement Fig. 1). All patients with a score
of 5 at six months also had a score of 5 at 30 days/hospital discharge
(Supplement Fig. 2). Most patients with a mRS score of 0 at three and
six months had improved since 30 days/hospital discharge (Supple-
ment Figs. 2 and 3). Of patients who had a mRS score of 0 at six
months, the majority also had a score of 0 at three months
(Supplement Fig. 3). Of the 66 patients with a mRS score of 5 at
30 days/hospital discharge, 12/66 (18.2%) died before 3 months, 11/
66 (16.7%) improved and 5/66 (7.6%) stayed the same; data were
missing for the remaining 38 (57.6%) (Supplement Fig. 4).
Fig. 1 – Flow of participants and data.
[1] 10 patients (5 TI, 5 i-gel) who did not consent to follow-up have unknown survival status.
[2] 1 patient (1 TI, 0 i-gel) who consented to active follow-up is known to have survived to 3 months but has unknown
survival status between 3 months and 6 months follow-up.
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Table 1 – Complete case modified Rankin Scale analyses results.
Complete case modified
Rankin Scale (03; good recovery)
Randomised to Tracheal
Intubation (n=4410)
Randomised to i-gel (n=4886) Odds Ratio
estimate (95% CI)
p-Value ICC Risk difference
estimate (95% CI)
p-Value
n (%) n (%)





0 (no symptoms) 124/4407 (2.8%) 117/4882 (2.4%)
1 48/4407 (1.1%) 41/4882 (0.8%)
2 50/4407 (1.1%) 58/4882 (1.2%)
3 78/4407 (1.8%) 95/4882 (1.9%)
4 46/4407 (1.0%) 45/4882 (0.9%)
5 27/4407 (0.6%) 39/4882 (0.8%)
6 (deceased) 4034/4407 (91.5%) 4487/4882 (91.9%)





0 (no symptoms) 52/4199 (1.2%) 55/4636 (1.2%)
1 6/4199 (0.1%) 4/4636 (0.1%)
2 30/4199 (0.7%) 35/4636 (0.8%)
3 35/4199 (0.8%) 27/4636 (0.6%)
4 22/4199 (0.5%) 17/4636 (0.4%)
5 5/4199 (0.1%) 4/4636 (0.1%)
6 (deceased) 4049/4199 (96.4%) 4494/4636 (96.9%)
Non-active consent patients who were not known
to have died at three months
164/4407 (4.7%) 186/4882 (5.0%)





0 (no symptoms) 59/4212 (1.4%) 66/4661 (1.4%)
1 4/4212 (0.1%) 5/4661 (0.1%)
2 42/4212 (1.0%) 41/4661 (0.9%)
3 29/4212 (0.7%) 24/4661 (0.5%)
4 18/4212 (0.4%) 18/4661 (0.4%)
5 2/4212 (0.1%) 3/4661 (0.1%)
6 (deceased) 4058/4212 (96.3%) 4504/4661 (96.6%)
Non-active consent patients who were not known
to have died at six months
158/4407 (4.4%) 180/4882 (4.5%)
a 7 patients (3 Tracheal Intubation, 4 i-gel) were unable to be identified at 30 days/hospital discharge and were excluded from this analysis.
b 104 patients (44 Tracheal Intubation, 60 i-gel) were missing mRS at 3 months follow-up and were excluded from the complete-case analysis at this timepoint.



























Table 2 – Complete case EQ-5D-5L index and visual analogue scale analyses results.
Randomised to Tracheal
Intubation (N = 4410)



















170/4205 (4.0%) 0.76 (0.50, 0.84) 185/4672 (4.0%) 0.71 (0.40, 0.84) 0.98 (0.79, 1.21) 0.86 0.92 (0.72, 1.18) 0.53
Three months post-
OHCAe
150/4199 (3.6%) 0.80 (0.67, 0.91) 144/4638 (3.1%) 0.81 (0.68, 1.0) 0.86 (0.68, 1.09) 0.22 1.07 (0.83, 1.38) 0.63




173/4208 (4.1%) 70 (50, 80) 182/4669 (3.9%) 65 (45, 80) 0.95 (0.76, 1.17) 0.63 0.81 (0.64, 1.03) 0.08
Three months post-
OHCAh
152/4201 (3.6%) 80 (60, 90) 145/4639 (3.1%) 80 (65, 90) 0.86 (0.68, 1.08) 0.19 1.08 (0.86, 1.35) 0.53
Six months post-OHCAi 159/4217 (3.8%) 80 (65, 90) 158/4662 (3.4%) 80 (65, 90) 0.89 (0.70, 1.13) 0.35 1.01 (0.80, 1.27) 0.94
Notes:
a Outcome is survivors vs non-survivors. Models were adjusted for ambulance service (4 levels), paramedic experience (2 levels: 5 years, <5 years) and
distance from base ambulance station (2 levels: 5 miles, <5 miles). Confidence intervals were adjusted for paramedic clustering using a clustered bootstrap.
b Outcome is either: (a) EQ-5D single summary index, or (b) EQ-5D visual analogue scale, conditional on surviving to the relevant timepoint. The outcomes were
transformed to a scale between 0 and 1 non-inclusive. Models were adjusted for trust (4 levels: YAS, SWAST EMAS and EEAST), paramedic experience (2 levels:
5 years, <5 years) and distance from base ambulance station (2 levels: 5 miles, <5 miles). Confidence intervals were adjusted for paramedic clustering using a
clustered bootstrap.
d Missing for 205 Tracheal Intubation group patients and 214 i-gel group patients.
e Missing for 211 Tracheal Intubation group patients and 248 i-gel group patients.
f Missing for 197 Tracheal Intubation group patients and 229 i-gel group patients.
g Missing for 202 Tracheal Intubation group patients and 217 i-gel group patients.
h Missing for 209 Tracheal Intubation group patients and 247 i-gel group patients.
i Missing for 193 Tracheal Intubation group patients and 224 i-gel group patients.
Fig. 2 – Main analyses of modified Rankin Scale scores.
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The mRS scores at all three timepoints showed higher proportions
of patients with a good recovery in the TI group compared to the i-gel
group but these differences were not statistically significant [complete
case analysis: 30 days/hospital discharge OR = 0.92 (95% CI 0.77-
1.09); three months OR = 0.89 (95% CI 0.69-1.14); six months
OR = 0.91 (95% CI 0.71-1.16)] (Table 1, Fig. 2)]. The ‘worst-case”’ and
‘imputed case’ sensitivity analyses provided consistent results
(Supplement Tables 1 and 2, Fig. 2).
The mRS scores at all three timepoints showed higher proportions
of patients with a good recovery in the TI group compared to the i-gel
group but these differences were not statistically significant [complete
case analysis: 30 days/hospital discharge OR = 0.92 (95% CI 0.77-
1.09); three months OR = 0.89 (95% CI 0.69-1.14); six months
OR = 0.91 (95% CI 0.71-1.16)] (Table 1, Fig. 2)]. The ‘worst-case”’ and
‘imputed case’ sensitivity analyses provided consistent results
(Supplement Tables 1 and 2, Fig. 2).
Fig. 3 – Main analyses of index scores.
Fig. 4 – Main analyses of visual analogue scale scores.
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The EQ-5D domain scores are shown in Supplement Table 3. The
data indicate higher median index and VAS scores at 30 days/hospital
discharge in the TI group and similar median scores at the later
timepoints (Table 2). The survival component of the two-part model
showed no statistically significant difference in the odds of survival in
the TI group compared to the i-gel group at all three timepoints
(Table 2, Figs. 3 and 4). For the quality of life component in survivors,
the outcomes were similar in the two groups at all timepoints for both
index and VAS scores (Table 2, Figs. 3 and 4). The sensitivity
analyses showed consistent findings with the complete case analyses
(Supplement Tables 4 and 5, Supplement Figs. 58).
The EQ-5D domain scores are shown in Supplement Table 3. The
data indicate higher median index and VAS scores at 30 days/hospital
discharge in the TI group and similar median scores at the later
timepoints (Table 2). The survival component of the two-part model
showed no statistically significant difference in the odds of survival in
the TI group compared to the i-gel group at all three timepoints
(Table 2, Figs. 3 and 4). For the quality of life component in survivors,
the outcomes were similar in the two groups at all timepoints for both
index and VAS scores (Table 2, Figs. 3 and 4). The sensitivity
analyses showed consistent findings with the complete case analyses
(Supplement Tables 4 and 5, Supplement Figs. 58).
Discussion
The functional outcomes (mRS scores) at 3 and 6 months for
patients recruited to the AIRWAYS-2 trial were consistent with the
primary outcome of mRS score measured at 30 days/hospital
discharge.11 The proportions of patients achieving a good
recovery were not statistically different between the two treatment
groups at all three timepoints. Quality of life measured using the
EQ-5D-5L also revealed no significant differences between the
two treatment groups across the three timepoints. The ‘worst
case’ and ‘imputed case’ sensitivity analyses, designed to
determine the potential impact of missing data, did not alter
these conclusions.
The majority of RCTs in OHCA have reported only short-term
outcomes, and even the most recent international advisory statement
describing a core outcome set for RCTs in OHCA patients does not
recommend data collection beyond 90 days, mainly because of the
substantial resources required and the risk of attrition bias.12 As a
result, the natural history of survivor recovery following OHCA has
been documented by only a few investigators,19,2325 and there
remains a need to examine the longer-term impacts of OHCA on
functional status, cognition and quality of life.26,27
Several studies have documented improvements in the functional
status of OHCA survivors for at least the first three months and up to six
months after cardiac arrest.25,26Our data support this: we have shown
a shift in the distribution of mRS scores consistent with improving
functional status between hospital discharge and three months, and
an attenuated shift in the same direction between three and six
months. The decrease in the proportion of patients with an mRS score
of 5 between hospital discharge and three months represents a
combination of some patients dying and others improving their
functional status.28
Although the PART trial documented a significantly higher rate of
favourable outcome among patients randomised to a strategy of initial
laryngeal tube SGA compared with TI,10 longer-term outcomes were
not collected, so it is unknown whether this difference was sustained at
three and six months after OHCA.
Our research has several limitations. In keeping with similar
studies, our trial has relatively few survivors from which to gather
longer-term outcomes. Furthermore, we were reliant on both active
patient consent and the participant's willingness to complete and
return the questionnaires at the follow-up timepoints. Despite
considerable effort by the research teams, only 52.4% of survivors
consented to active follow up and only 41.3% of survivors were
followed up to six months. As a result, our analyses are undermined by
missing data, with limited trial power and the risk of attrition bias.
However, the proportion of missing data is very similar in the two
groups, and there is no evidence that the availability of follow-up data
was influenced by patient allocation. Furthermore, the sensitivity
analyses reported did not alter our conclusions about the two
treatment strategies. Other limitations relevant to the wider trial are
described in a previous paper.11 Importantly, the trial population
included patients who did and did not receive AAM, and paramedics
allocated to the i-gel group were more likely to use an advanced
technique than those allocated to TI.
Conclusions
Longer term follow-up confirmed the results of the AIRWAYS-2
primary analysis. There were no significant differences in functional
outcome or quality of life between the i-gel SGA and TI groups at three
and six months after OHCA. This suggests that our initially reported
findings are robust over time.
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